AMATI, FRANCESCO
 Distribuzione geografica
Continente #
NA - Nord America 318
EU - Europa 286
AS - Asia 115
AF - Africa 6
SA - Sud America 3
OC - Oceania 2
Totale 730
Nazione #
US - Stati Uniti d'America 317
CN - Cina 85
FI - Finlandia 85
IE - Irlanda 71
IT - Italia 36
DE - Germania 35
SE - Svezia 26
RU - Federazione Russa 19
IN - India 18
GB - Regno Unito 8
HK - Hong Kong 5
JP - Giappone 5
NG - Nigeria 4
AU - Australia 2
KE - Kenya 2
NL - Olanda 2
PE - Perù 2
AR - Argentina 1
AT - Austria 1
BE - Belgio 1
CA - Canada 1
FR - Francia 1
KR - Corea 1
PH - Filippine 1
UA - Ucraina 1
Totale 730
Città #
Helsinki 85
Shanghai 84
Boardman 81
New York 72
Dublin 71
Ashburn 53
Moscow 19
Pune 16
Chandler 14
Falkenstein 6
Naples 6
Casal di Principe 5
Los Angeles 5
Milan 5
Wanchai 5
Benin City 4
Hanover 4
Dolianova 3
Guildford 3
London 3
Phoenix 3
Asagayakita 2
Berlin 2
Daiba 2
Frankfurt am Main 2
Lawrence 2
Lima 2
Nairobi 2
Princeton 2
Ragusa 2
Sankt Augustin 2
Sydney 2
Verona 2
Amsterdam 1
Brussels 1
Camden 1
Castellammare di Stabia 1
Concepción del Uruguay 1
Council Bluffs 1
Hangzhou 1
Heeten 1
Matsuyama 1
Mumbai 1
Paris 1
Suncheon-si 1
Tandag 1
Taunton 1
Winnipeg 1
Totale 586
Nome #
Diagnosis and management of patients with alpha 1-antitrypsin deficiency: an Italian perspective 40
COVID-19 in Immunocompromised Patients: A Systematic Review 40
Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases 32
COVID-19 in lung transplant recipients: A case series from Milan, Italy 23
How to Identify Causes and Predisposing Factors in Bronchiectasis 22
An extensive bundle of tests is needed to detect treatable causes of bronchiectasis (Bx) 22
Respiratory failure in COVID-19: a patient's perspective and clinical cases 20
Post-COVID-19 sequelae 20
Cardiovascular Complications in Community-Acquired Pneumonia 19
COVID-19 Network: the response of an Italian Reference Institute to research challenges about a new pandemia 18
Comparison of different conditions for DNA extraction in sputum - a pilot study 17
COVID-19 multidisciplinary high dependency unit: the Milan model 17
Cardiovascular side-effects of common antibiotics 17
Community-acquired pneumonia 17
Investigating the Etiology of Bronchiectasis: You Do Not Find What You Do Not Look For 17
Antibiotics for lung disease and cancer 17
Comparison of different sets of immunological tests to identify treatable immunodeficiencies in adult bronchiectasis patients 16
Genetic and Serum Screening for Alpha-1-Antitrypsin Deficiency in Adult Patients with Cystic Fibrosis: A Single-Center Experience 16
Alpha1-Antitrypsin Inherited Variants in Patients With Bronchiectasis 15
Aspiration risks factors, microbiology and empiric antibiotics for patients hospitalized with community-acquired pneumonia 15
Protease-Antiprotease Imbalance in Bronchiectasis 14
Onset of systemic arterial hypertension after initiation of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A case series 14
What is the best technique to extract bacterial DNA from sputum? 14
Early Phases of COVID-19 Are Characterized by a Reduction in Lymphocyte Populations and the Presence of Atypical Monocytes 13
Bacterial Patterns and Empiric Antibiotic Use in COPD Patients With Community-Acquired Pneumonia 13
Hepatic and pulmonary involvement in a patient with PR3-ANCA vasculitis following SARS-CoV-2 vaccination: a case report 13
Neutrophil elastase in bronchiectasis 13
Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia 13
Site of care and multidisciplinary approach 13
Diagnosis and Initial Investigation of Bronchiectasis 13
Microbial Dysregulation of the Gut-Lung Axis in Bronchiectasis 13
Treatable traits in interstitial lung diseases: a call to action 11
Innate and Adaptive Lymphocytes in Non-Tuberculous Mycobacteria Lung Disease: A Review 11
When and how ruling out cystic fibrosis in adult patients with bronchiectasis 11
The biology of pulmonary exacerbations in bronchiectasis 11
Lung Recruitability of COVID-19 Pneumonia in Patients Undergoing Helmet CPAP 10
Risk factors and guideline adherence of empiric antibiotic use in community-acquired pneumonia 10
Prognostic parameters of in-hospital mortality in COVID-19 patients-An Italian experience 10
Identify Drug-Resistant Pathogens in Patients with Community-Acquired Pneumonia 10
SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity 10
Emerging Resistance of Gram Negative Pathogens in Community-Acquired Pneumonia 10
Overweight and obesity in adults with cystic fibrosis: An Italian multicenter cohort study 9
Respiratory viruses in stable bronchiectasis: A multicenter evaluation in Northern Italy 9
Phenotyping in bronchiectasis: are we moving toward a personalized medicine? 9
Dysregulation of the microbial ‘gut-lung’ axis in bronchiectasis 8
Predictors of Helmet CPAP Failure in COVID-19 Pneumonia: A Prospective, Multicenter, and Observational Cohort Study 8
Glucocorticoid Therapy in COVID-19 7
Prognostic value of copeptin and mid-regional proadrenomedullin in COVID-19-hospitalized patients 7
Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review 7
Pro-resolving and pro-inflammatory fatty acid-derived mediators in sputum of stable state bronchiectasis patients 7
Unmet needs and perspectives in rheumatoid arthritis-associated interstitial lung disease: A critical review 7
One Size Does Not Fit All: Moving Towards a Personalized Approach for Steroids in COVID-19 7
Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis 7
Nontuberculous mycobacteria infection and pulmonary disease in bronchiectasis 7
Microbial Inflammatory Networks in Bronchiectasis Exacerbators With Pseudomonas aeruginosa 6
Switching to nebulised short acting bronchodilators does not increase the risk of arrhythmia in patients hospitalized with a COPD exacerbation 6
T2-High Endotype and Response to Biological Treatments in Patients with Bronchiectasis 6
Heterogeneity of weight gain after initiation of Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis 5
Treatable Traits in Systemic Sclerosis 3
Totale 795
Categoria #
all - tutte 6.528
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.528


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202211 0 0 0 0 0 0 0 0 2 3 4 2
2022/2023228 4 3 3 5 6 0 66 8 32 63 27 11
2023/2024556 53 64 132 68 33 107 68 31 0 0 0 0
Totale 795